<p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）在週三發佈的研究報告中，由 StockNews.com 的股票研究分析師將其評級從 “買入” 上調至 “強烈買入”。</p>
<ul>
<li>諾和諾德推出 Wegovy，成為三重威脅</li>
</ul>
<p>另外，Argus 將賽諾菲的股票目標價從 55.00 美元上調至 60.00 美元，並在 7 月 26 日星期五的研究報告中給予該公司 “買入” 評級。三位投資分析師對該股票進行了持有評級，兩位給予買入評級，一位給予強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “中等買入”，平均目標價為 57.50 美元。</p>
<p><strong>查看我們關於 SNY 的最新報告</strong></p>
<h2>賽諾菲股票表現</h2>
<ul>
<li>6 個購買輝瑞製藥股票的理由</li>
</ul>
<p>賽諾菲股票週三開盤價為 56.32 美元。賽諾菲的 12 個月最低價為 42.63 美元，最高價為 56.57 美元。該公司的市值為 1426.4 億美元，市盈率為 28.30，市盈增長比為 1.56，貝塔係數為 0.59。該企業的 50 天簡單移動平均線為 51.20 美元，200 天簡單移動平均線為 49.17 美元。該公司的資產負債比為 0.17，流動比率為 1.00，速動比率為 0.65。</p>
<p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）於 7 月 25 日星期四公佈了季度收益數據。該公司報告本季度每股收益為 0.93 美元，超過了 0.88 美元的共識預期 0.05 美元。本季度營收為 107.5 億美元，低於分析師預期的 168.6 億美元。賽諾菲的淨利潤率為 9.60%，淨資產回報率為 26.29%。該業務的營收同比增長了 7.8%。去年同期，該公司每股收益為 0.95 美元。根據股票研究分析師的平均預期，預計賽諾菲今年將實現每股收益 4.19 美元。</p>
<h2>賽諾菲機構交易</h2>
<ul>
<li>投資的 20 個最佳醫療保健股</li>
</ul>
<p>對該公司的股票進行了買賣的對沖基金。TCTC Holdings LLC 在第一季度增持了賽諾菲股票，持股增長了 28.0%。TCTC Holdings LLC 現在擁有 960 股該公司股票，價值 47000 美元，上季度購入了額外的 210 股。HB Wealth Management LLC 在第二季度增持了賽諾菲股票，持股增長了 3.7%。HB Wealth Management LLC 現在擁有 6166 股該公司股票，價值 299000 美元，上季度購入了額外的 221 股。Wynn Capital LLC 在第一季度增持了賽諾菲股票，持股增長了 4.5%。Wynn Capital LLC 現在擁有 5266 股該公司股票，價值 256000 美元，上季度購入了額外的 226 股。Insigneo Advisory Services LLC 在第二季度增持了賽諾菲股票，持股增長了 3.3%。Insigneo Advisory Services LLC 現在擁有 7212 股該公司股票，價值 371000 美元，上季度購入了額外的 228 股。最後，Angeles Investment Advisors LLC 在第四季度增持了賽諾菲股票，持股增長了 2.1%。Angeles Investment Advisors LLC 現在擁有 12029 股該公司股票，價值 598000 美元，上季度購入了額外的 244 股。該股票的 10.04% 由對沖基金和其他機構投資者持有。</p>
<h2>賽諾菲公司簡介（獲取免費報告）</h2>
<p>賽諾菲是一家從事在美國、歐洲和國際市場研究、開發、生產和營銷治療方案的醫療保健公司。其業務涵蓋製藥、疫苗和消費者保健領域。該公司提供特殊護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；治療糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們比賽諾菲更喜歡的五支股票</li>
<li>什麼是標準普爾 500 指數，以及它與其他指數的區別</li>
<li>研究：退休人員從兼職工作中賺取多少錢？</li>
<li>市盈率計算：如何評估股票</li>
<li>Brinker International 因盈利不及預期而提供回調機會</li>
<li>對投資者最重要的沃倫·巴菲特股票：他自己的</li>
<li>Globant 是一個新興的人工智能投資，正在擴大其業務範圍</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 抓住這隻支付 22% 股息的 ETF（來自 Investors Alley）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDE2"/></p>
<h2>您現在是否應該投資 1000 美元購買賽諾菲股票？</h2>
<p>在考慮賽諾菲之前，您可能希望聽聽這個。</p>
<p>MarketBeat 追蹤華爾街頂級評級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而賽諾菲不在名單上。</p>
<p>雖然賽諾菲目前在分析師中有 “持有” 評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

賽諾菲

<p>StockNews.com 將賽諾菲（納斯達克股票代碼：SNY）的評級從 “買入” 上調至 “強烈買入”。此外，Argus 設定了更高的目標股價，並維持了 “買入” 評級。目前，賽諾菲的平均評級為 “中等買入”，目標股價為 XX 美元。股價開盤為 XX 美元，12 個月內最低為 XX 美元，最高為 XX 美元。最近一個季度的收益每股為 XX 美元，超過了預期。分析師預測今年的每股收益為 4.19 美元。機構投資者持有該股的 10.04%</p>

<p>Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by equities research analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Wednesday.</p>
<ul>
<li>Novo Nordisk Arms Wegovy to Be a Triple Threat</li>
</ul>
<div class="lb-trans"><p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）在週三發佈的研究報告中，由 StockNews.com 的股票研究分析師將其評級從 “買入” 上調至 “強烈買入”。</p>
<ul>
<li>諾和諾德推出 Wegovy，成為三重威脅</li>
</ul>
</div><p>Separately, Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $57.50.</p>
<div class="lb-trans"><p>另外，Argus 將賽諾菲的股票目標價從 55.00 美元上調至 60.00 美元，並在 7 月 26 日星期五的研究報告中給予該公司 “買入” 評級。三位投資分析師對該股票進行了持有評級，兩位給予買入評級，一位給予強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “中等買入”，平均目標價為 57.50 美元。</p>
</div><p><strong>View Our Latest Report on SNY</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 SNY 的最新報告</strong></p>
</div><h2>Sanofi Stock Performance</h2>
<ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><h2>賽諾菲股票表現</h2>
<ul>
<li>6 個購買輝瑞製藥股票的理由</li>
</ul>
</div><p>Shares of SNY stock opened at $56.32 on Wednesday. Sanofi has a 12-month low of $42.63 and a 12-month high of $56.57. The firm has a market capitalization of $142.64 billion, a price-to-earnings ratio of 28.30, a price-to-earnings-growth ratio of 1.56 and a beta of 0.59. The business has a 50 day simple moving average of $51.20 and a 200 day simple moving average of $49.17. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.</p>
<div class="lb-trans"><p>賽諾菲股票週三開盤價為 56.32 美元。賽諾菲的 12 個月最低價為 42.63 美元，最高價為 56.57 美元。該公司的市值為 1426.4 億美元，市盈率為 28.30，市盈增長比為 1.56，貝塔係數為 0.59。該企業的 50 天簡單移動平均線為 51.20 美元，200 天簡單移動平均線為 49.17 美元。該公司的資產負債比為 0.17，流動比率為 1.00，速動比率為 0.65。</p>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analysts' expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business's revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $0.95 earnings per share. On average, equities research analysts anticipate that Sanofi will post 4.19 EPS for the current year.</p>
<div class="lb-trans"><p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）於 7 月 25 日星期四公佈了季度收益數據。該公司報告本季度每股收益為 0.93 美元，超過了 0.88 美元的共識預期 0.05 美元。本季度營收為 107.5 億美元，低於分析師預期的 168.6 億美元。賽諾菲的淨利潤率為 9.60%，淨資產回報率為 26.29%。該業務的營收同比增長了 7.8%。去年同期，該公司每股收益為 0.95 美元。根據股票研究分析師的平均預期，預計賽諾菲今年將實現每股收益 4.19 美元。</p>
</div><h2>Institutional Trading of Sanofi</h2>
<ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><h2>賽諾菲機構交易</h2>
<ul>
<li>投資的 20 個最佳醫療保健股</li>
</ul>
</div><p>Hedge funds have recently bought and sold shares of the company. TCTC Holdings LLC grew its holdings in shares of Sanofi by 28.0% during the first quarter. TCTC Holdings LLC now owns 960 shares of the company's stock valued at $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC grew its stake in Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after acquiring an additional 221 shares in the last quarter. Wynn Capital LLC increased its holdings in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company's stock valued at $256,000 after purchasing an additional 226 shares during the period. Insigneo Advisory Services LLC lifted its position in shares of Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock worth $371,000 after purchasing an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC boosted its holdings in shares of Sanofi by 2.1% during the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company's stock worth $598,000 after purchasing an additional 244 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對該公司的股票進行了買賣的對沖基金。TCTC Holdings LLC 在第一季度增持了賽諾菲股票，持股增長了 28.0%。TCTC Holdings LLC 現在擁有 960 股該公司股票，價值 47000 美元，上季度購入了額外的 210 股。HB Wealth Management LLC 在第二季度增持了賽諾菲股票，持股增長了 3.7%。HB Wealth Management LLC 現在擁有 6166 股該公司股票，價值 299000 美元，上季度購入了額外的 221 股。Wynn Capital LLC 在第一季度增持了賽諾菲股票，持股增長了 4.5%。Wynn Capital LLC 現在擁有 5266 股該公司股票，價值 256000 美元，上季度購入了額外的 226 股。Insigneo Advisory Services LLC 在第二季度增持了賽諾菲股票，持股增長了 3.3%。Insigneo Advisory Services LLC 現在擁有 7212 股該公司股票，價值 371000 美元，上季度購入了額外的 228 股。最後，Angeles Investment Advisors LLC 在第四季度增持了賽諾菲股票，持股增長了 2.1%。Angeles Investment Advisors LLC 現在擁有 12029 股該公司股票，價值 598000 美元，上季度購入了額外的 244 股。該股票的 10.04% 由對沖基金和其他機構投資者持有。</p>
</div><h2>Sanofi Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>賽諾菲公司簡介（獲取免費報告）</h2>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>賽諾菲是一家從事在美國、歐洲和國際市場研究、開發、生產和營銷治療方案的醫療保健公司。其業務涵蓋製藥、疫苗和消費者保健領域。該公司提供特殊護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；治療糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Sanofi</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>Study: How Much Are Retirees Earning from Side Hustles in 2024?</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Brinker International Offers a Pullback Opportunity on EPS Miss</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Globant Is an Emerging AI Play That’s Expanding Its Footprint</li>
</ul>
<div class="lb-trans"><h2>進一步閲讀</h2>
<ul>
<li>我們比賽諾菲更喜歡的五支股票</li>
<li>什麼是標準普爾 500 指數，以及它與其他指數的區別</li>
<li>研究：退休人員從兼職工作中賺取多少錢？</li>
<li>市盈率計算：如何評估股票</li>
<li>Brinker International 因盈利不及預期而提供回調機會</li>
<li>對投資者最重要的沃倫·巴菲特股票：他自己的</li>
<li>Globant 是一個新興的人工智能投資，正在擴大其業務範圍</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Grab this ETF paying a huge 22% dividend (From Investors Alley)(Ad)</p>
<div class="lb-trans"><p>→ 抓住這隻支付 22% 股息的 ETF（來自 Investors Alley）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDE2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9016&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sanofi right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1000 美元購買賽諾菲股票？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮賽諾菲之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂級評級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而賽諾菲不在名單上。</p>
</div><p>While Sanofi currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽諾菲目前在分析師中有 “持有” 評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

StockNews.com 將賽諾菲（NASDAQ:SNY）的評級上調至強力買入